Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2024

Zaun Gregor, Borchert Sabrina, Metzenmacher Martin, Lueong Smiths, Wiesweg Marcel, Zaun Yasmin, Pogorzelski Michael, Behrens Franziska, Schildhaus Hans-Ulrich, Virchow Isabel, Kasper Stefan, Schuler Martin, Theurer Sarah, Liffers Sven

Abstract excerpt

PURPOSE: Current guidelines recommend combination chemotherapy for treatment of patients with unfavorable cancer of unknown primary (CUP). Biomarker-guided targeted therapies may offer additional benefit. Data on the feasibility and effectiveness of comprehensive genomic biomarker profiling of CUP in a standard clinical practice setting are limited. METHODS: This analysis included 156 patients with confirmed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms, Unknown Primary

Share to Precision Medicine

Source

Identifiers

PMID: 38316065
DOI: 10.1016/j.ejca.2024.113540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.PMID 38316065Read ↗

A prospective national precision medicine trial comparing blood and tissue profiling in patients with Cancer of Unknown Primary (CUPCOMP)Semantic proximity Read ↗

Comprehensive ctDNA Profiling Enables Tissue-of-Origin Prediction and Actionable Biomarker Detection in Cancer of Unknown PrimarySemantic proximity Read ↗

Cancer of unknown primary (CUP) through the lens of precision oncology – a single institution perspectiveSemantic proximity Read ↗

Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.Semantic proximity Read ↗

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.Semantic proximity Read ↗

Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.Semantic proximity Read ↗

Cancer of unknown primary.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.Semantic proximity Read ↗

Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patientsSemantic proximity Read ↗

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimarySemantic proximity Read ↗

Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patientsSemantic proximity Read ↗

Real-world data analysis of patients with cancer of unknown primarySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.